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ABSTRACT 
DNA repair is not a single mechanism found within cells. There exists numerous different DNA 
repair mechanisms that function within every type of cell. The majority of these mechanisms risk 
accumulating mutations. However, there are a few repair mechanisms that are known to be error-
free and one of these is direct reversal repair. This study focused on two proteins highly involved 
in direct reversal DNA repair—ALKBH2 and ALKBH3. Previous studies have shown that in 
mice, these two proteins play a significant role in preventing and repairing DNA damage due to 
methylation as well as decreasing the frequency of mutagenic alkyl adducts. The goal of this 
study was to characterize the roles of the direct reversal repair proteins in human cells. We 
expected to see a similar phenotype to that of the Alkbh2 and Alkbh3-deficient mice. Telomerase 
immortalized human skin fibroblasts were targeted for the ALKBH2 and ALKBH3 alleles using a 
RNA-guided CRISPR-Cas9 construct that was designed to induce double stranded DNA breaks 
within the exons and disrupt the open reading frame, eliminating protein activity. Isolated clones 
were analyzed using fragment analysis and DNA sequencing to characterize any alterations in the 
open reading frame of the genes. Through sequencing analysis, results showed that one clone was 
successfully targeted for one of the ALKBH3 alleles with a single nucleotide insertion in its 
sequence, causing a disruption of the open reading frame. Though the ultimate goal of the 
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experiment was not attained, we concluded that HTERTG fibroblasts can be expanded to serve as 
a model in which to construct targeted human cell lines that have near normal karyotypes.  
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INTRODUCTION 
Direct reversal repair eliminates some DNA and RNA modifications without using 
excision, resynthesis, and ligation. Therefore, because direct reversal repair does not require 
breaking of the phosphodiester backbone, it is error-free and preserves genetic information. 
Direct reversal is primarily utilized in correcting damage caused by DNA alkylating agents 
including N-methyl-N’-nitro-N-nitrosoguanidine (MNNG), N-methyl-N-nitrosourea (MNU), and 
methyl methanesulfonate (MMS) that react with DNA to produce various O-alkylated and N-
alkylated products. Two major types of proteins conduct direct reversal repair, O6-
methylguanine-DNA methyltransferases and ALKBH α-ketoglutarateFe(II) dioxygenases 
(FeKGDs) (Fu et al., 2012). Although there are numerous methyltransferases in mammalian cells, 
those enzymes generally catalyze transfer of methyl groups to DNA or transfer of methyl groups 
to or from proteins (Copeland et al., 2009; Jin and Robertson, 2013; Loenarz and Schofield, 
2011). In mammalian cells, there is only a single DNA methyltransferase protein, O6-
methylguanine-DNA methyltransferase (MGMT or AGT), that removes methyl groups at 
exocyclic ring oxygens of DNA (Pegg, 1990). The other type of direct reversal repair is 
performed by ALKBH proteins that are members of a superfamily of FeKGDs (Aravind and 
Koonin, 2001; Loenarz and Schofield, 2011). Though the ALKBH family of FeKGDs 
encompasses nine proteins with conserved active site domains, removal of alkyl damage in DNA 
has only been established for four family members, ALKBH1 – 3 and FTO (Aravind and Koonin, 
2001). Unlike repair by MGMT, which is inactivated following a single repair reaction, each 
ALKBH protein can catalyze numerous repair reactions to eliminate N-modifications of cytosine, 
adenine, thymine and guanine residues (Loenarz and Schofield, 2011). In this review, prior to 
description of the direct reversal DNA repair enzymes and their functions, we will briefly 
describe sources of alkylation damage and adducts that are introduced upon exposure of cells to 
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alkylating agents.  
 
1.1. Sources of alkylation damage 
 
 Alkylating agents are present in the exogenous environment as well as intracellularly via 
oxidative metabolism. Alkylation damage from exposure to exogenous sources such as N-methyl-
N’-nitro-N-nitrosoguanidine (MNNG), N-methyl-N-nitrosourea (MNU), and methyl 
methanesulfonate (MMS) (Figure 1B and 1D) (Eker et al., 2009) can arise from environmental 
agents present in various media including air, water, plants, and food (Ballschmiter, 2003). 
Furthermore, numerous alkylating agents are used in chemotherapy to attack rapidly dividing 
tumor cells (Oesch and Klein, 1992). In addition to exogenous sources of DNA damage, a 
number of putative endogenous alkylating agents also are proposed (Figure 1E). Endogenous 
agents can also introduce alkylation damage as a consequence of cellular metabolism	  (De Bont 
and van Larebeke, 2004). Among the possible alkylating agents implicated is the enzyme cofactor 
S-adenosylmethionine (SAM), which is involved in numerous biochemical processes	  (Rydberg 
Figure 1. Alkylation mechanisms and selected alkylating agents. (A) SN1 alkylating agent 
mechanism, (B) examples of SN1 alkylating agents, TMZ-temozolomide, (C) SN2 alkylating agent 
mechanism, (D) examples of SN2 alkylating agents (E) examples of alkylating agents that can form 
cyclized adducts with DNA bases, CAA-Chloroacetaldehyde, MDA-Malondialdehyde, (F) examples of 
endogenous methylating agents. 
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and Lindahl, 1982). Methylating agents can also be formed via enzymatically-catalyzed chemical 
nitrosation reactions	  (Taverna and Sedgwick, 1996). These nitrosation reactions can activate 
choline and betaine, as well as other lipoperoxidation products (Figure 1F) (De Bont and van 
Larebeke, 2004; Lawley, 1966; Taverna and Sedgwick, 1996). Regardless of whether sources are 
exogenous or endogenous, reaction of alkylating agents with DNA and RNA generates adducts 
that can disrupt major cellular processes such as replication and transcription, which can trigger 
cell cycle checkpoints and initiate apoptosis	  (Drablos et al., 2004). Importantly, if DNA alkyl 
adducts are left unrepaired, replication of damaged DNA can result in formation of mutations 
that, depending on the site within the genome, can lead to long term effects on cellular function. 
 
1.2. Types of alkylating agents 
 
The two major types of alkylating agents are SN1 (Figure 1A) and SN2 (Figure 1C). In 
the SN1 reaction mechanism, a charged ionic species forms that is generally the rate limiting step 
(monomolecular) (Figure 1A); whereas SN2 reactions follow bimolecular kinetics (Figure 1C). 
Alkylating agents are generally electrophilic compounds that have an affinity for the nucleophilic 
centers in organic macromolecules and react in either a mono- or bifunctional manner	  (Lawley, 
1966; Shackleton and Roberts, 1978; Singer, 1975). Monofunctional agents consist of a single 
reactive group that interacts covalently with a nucleophilic center in DNA and primarily modify 
ring nitrogens	  (Drablos et al., 2004; Singer, 1983). Common monofunctional nucleophilic 
reaction centers in DNA include: adenine N1, N3, N6; guanine N7, N1, N2, N3, N7, and O6; 
cytosine N3, N4, and O2; and thymine N3, O2, and O4 (Figure 2A), as well as phosphate 
modifications that form phosphotriesters (Figure 2B) (Singer, 1986). Bifunctional alkylating 
agents, on the other hand, have two reactive groups that can interact with the DNA and can form 
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cyclized or cross-linked DNA bases in addition to alkylating ring nitrogens (e.g., Melphelan and 
Nitrogen Mustard (Figure 1B and 1E)) (Drablos et al., 2004; Singer, 1983). 
 
1.3. Distribution of DNA Damage manifested by simple alkyating agents 
 
 Alkylating agents can cause damage at all exocyclic nitrogens and oxygens in DNA and 
RNA, as well as at ring nitrogens (Figure 2A) (Singer, 1983). However, the alkylation pattern 
depends on the alkylating agent, the position in DNA or RNA, and whether nucleic acids are 
single- or double-stranded (Table 1)	  (Drablos et al., 2004). Interestingly, O-alkylations are more 
mutagenic and harmful than N-alkylations, which may be more cytotoxic, but not as mutagenic	  
(Drablos et al., 2004). 
 
Some frequent methylation sites in DNA include 1-methylguanine (1-meG), O6-
methylguanine (O6-meG), 7-methylguanine (7-meG), 3-methylguanine (3-meG), 3-
methylcytosine (3-meC), and 3-methyladenine (3-meA) (Figure 2A)	  (De Bont and van Larebeke, 
2004; Eker et al., 2009). Importantly, nitrogens at base pairing positions in double-stranded DNA 
are less susceptible to alkylation damage than those found in single-stranded regions of DNA; 
 
Figure 2. DNA Watson-Crick base pairs with principal damage sites modified by small alkylating 
agents (methyl and ethyl). (A) Sites of base modification by SN1 and SN2 alkylating agents. The orange 
indicates major damage sites and the green minor damage sites. (B) Phosphotriester formation indicated 
by the presence of methyl groups, along with the Rp and Sp isomers. 
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though, methylating agents can react at Watson-Crick hydrogen bonding sites when DNA is 
singe-stranded. As a result, 1-meA and 3-meC adducts are much more frequent in single-stranded 
than in double-stranded DNA (Table 1).  
 
Base modifications caused by larger ethylating agents (Table 1) begin to show 
differences from the corresponding methylating agents in site specificity. Ethyl methanesulfonate 
(EMS) reacts similarly with guanine ring nitrogens compared to the methyl methanesulfonate 
(MMS), but there is a small, yet significant, decrease in the percentage of 1-meA and 3-meC 
formed by that agent. On the contrary, 1-ethyl-1-nitrosourea (ENU) produces significantly less 7-
ethylguanine compared to the percentage of 7-meG formed by exposure to 1-methyl-1-
nitrosourea (MNU) (Table 1). The decrease in modification at the N7 position of guanine (G) is 
accompanied by a concomitant increase in the formation of phosphotriesters by ENU that 
represents over 50% of the damage assayed. 
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Table 1. Alkylating agent damage from SN1 or SN2 methylating and ethylating agents [17]. 
Alkylating 
Agent MMS (SN2) MNU (SN1) EMS (SN2) ENU (SN1) 
Strand ssDNA dsDNA ssDNA dsDNA ssDNA dsDNA ssDNA dsDNA 
Alkylation Site Adenine 
N1 18.0 3.8 2.8 1.3 8.0 1.7 2.0 0.2 
N3 1.4 10.4 2.6 9.0 1.0 4.9 1.2 4.0 
N7 3.8 1.8 1.8 1.7 3.0 1.1 0.6 0.3 
Alkylation Site Guanine 
N3 1.0 0.6 0.4 0.8 1.0 0.9 0.5 0.6 
O6 nd 0.3 3.0 6.3 1.0 2.0 7.0 7.8 
N7 68.0 85.0 69.0 67.0 77.0 65.0 10.0 11.5 
Alkylation Site Thymine 
O2 nd nd nd 0.1 nd nd 6.0 7.4 
N3 nd 0.8 nd 0.3 nd nd nd 0.8 
O4 nd nd nd 0.4 nd nd 4.0 2.5 
Alkylation Site Cytosine 
O2 nd nd nd 0.1  nd 5.0 3.5 
N3 10.0 <1.0 2.3 0.6 5.0 0.6 1.7 0.2 
 Phosphodiester 
 2.0 0.8 ~10.0 16.0 10.0 13.0 65.0 57.0 
nd-not determined or detected, MMS-methyl methanesulfonate, MNU-1-methyl-1-nitrosourea,                                    
EMS-ethyl methanesulfonate, ENU-1-ethyl-1-nitrosourea 
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Given the number and importance of alkylating agents, much effort has been expended to study 
the biological effects of alkylated DNA in cells. Interestingly, the biological consequences of 
unrepaired alkylation damage vary depending on the site in DNA. For instance, exposure of 
double-stranded DNA to SN1 or SN2 alkylating agents results in more frequent generation of 7-
meG and 3-meA; however, the consequences of unrepaired 7-meG and 3-meA are different. 
Specifically, 7-meG does not block DNA replication and therefore is not as cytotoxic as 3-meA, 
whereas 3-meA adducts do not change the coding specificity of the base like 7-meG (De Bont 
and van Larebeke, 2004). In contrast, 7-meG can spontaneously depurinate and indirectly can 
lead to mutations at the apurinic sites that form. Furthermore, although both 7-meG and 3-meA 
modifications destabilize the glycosylic linkages, 3-meA repair occurs much more rapidly than 7-
meG. Though not formed as frequently as 3-meA and 7-meG adducts, 3-meT and 3-meC lesions 
block DNA synthesis (Huff and Topal, 1987). Additionally, generation of 1-meA and 3-meC 
modifications, primarily in single-stranded DNA regions will also halt DNA polymerization 
(Singer, 1983). Unique to O6-meG, unrepaired damage is both cytotoxic and mutagenic (Singer, 
1983). 
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2. Repair of DNA alkylation damage  
 
The diversity of the types of DNA alkylation damage necessitates the involvement of a 
number of DNA repair systems to eliminate the ensemble of alkylation damage. As this thesis is 
focused on direct reversal repair mechanisms, we will only mention other major systems 
implicated in repair of alkylation damage in this section (Figure 3). Major repair pathways 
include base excision repair (BER) and nucleotide excision repair (NER), which require removal 
of the damage followed by resynthesis and ligation (Figure 3) (Fu et al., 2012). Additionally, 
alkylation damage that persists during replication can lead to double strand breaks which are 
repaired by either non-homologous end-joining (NHEJ) or homologous recombination (HR) 
mechanisms (Andreassen et al., 2006; Jowsey et al., 2012; Vazquez et al., 2008). 
 
3. ALKBH Fe(II)/ α-ketoglutarate-dependent dioxygenases direct reversal repair 
 
The ALKBH family constitutes the direct reversal DNA repair proteins found in 
mammalian cells. The AlkB protein was initially discovered in E. coli. Though AlkB was 
	  
Figure 3. DNA repair systems that regenerate genetic information for the major purine bases damaged 
by methylating agents. O6-methylguanine-DNA methyltransferase and FeKGDs -a-ketoglutarate Fe(II) 
dioxygenases represent direct reversal repair. BER (base excision repair) and NER (nucleotide excision 
repair) make breaks in the DNA backbone and require complete removal of the base or an 
oligodeoxyribonucleotide. 
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originally identified using a screen for methyl methanesulfonate (MMS) sensitive mutants 
(Kataoka et al., 1983), it took almost 20 years to classify AlkB as part of the FeKGD superfamily 
(Aravind and Koonin, 2001) and to demonstrate its ability to reverse 1-meA and 3-meC damage 
via oxidative demethylation (Falnes et al., 2002; Trewick et al., 2002). Two human homologs of 
AlkB, ALKBH2 and ALKBH3, were subsequently confirmed to be oxidative DNA demethylases 
(Aas et al., 2003; Aronoff et al., 2003). DNA adducts that are typically repaired by ALKBH 
proteins are 1-meA, 3-meC, 1-meG, 3-meT, 1-etA, 3-etC, as well as etheno adducts, 1,N6-
ethenoadenine, and 3,N4-ethenocytosine (Aravind and Koonin, 2001; Falnes et al., 2002; Frick et 
al., 2007; Kataoka et al., 1983) (Figure 4). Additionally, bacterial AlkB and mammalian 
ALKBH3 also repair alkyl adducts in RNA (Aas et al., 2003). 
 
The ALKBH family consists of nine human ALKBH enzymes, ALKBH1-8 and the Fat 
Mass and Obesity associated gene (FTO) (Fu et al., 2012; Gerken et al., 2007; Kurowski et al., 
2003). Despite primary structure conservation, only ALKBH1-3 and FTO have demonstrated 
unambiguous DNA repair activity (Aravind and Koonin, 2001; Gerken et al., 2007; Kurowski et 
al., 2003). The prototypical substrates for ALKBH1-3 are 1-meA and 1-meC adducts, but other 
modifications can also be substrates for those proteins (Figure 3). Cells that are deficient in 
Figure 4. Numerous bases repaired by ALKBH2 and/or ALKBH3 proteins. (A) Methylated bases 
(B) Exocyclic 5-member ring bifunctional etheno (e) adducts (C) Exocyclic 6-member ring bifunctional 
a-hydroxypropano-dG (a-OH-PdG), g-hydroxypropano-dG (g-OH-PdG), and M1dG.	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ALKBH proteins generally show a higher sensitivity to SN2 type alkylating agents and a higher 
mutant frequency (Delaney and Essigmann, 2004; Nay et al., 2012; Ringvoll et al., 2006). 
Adducts repaired by ALKBH proteins are considered cytotoxic because they prevent hydrogen 
bonding with a complementary nucleotide and thus arrest DNA and RNA synthesis (Sedgwick et 
al., 2006), blocking replication and transcription, which leads to apoptosis (Falnes et al., 2002; 
Hornbeck et al., 2012; Kataoka et al., 1983; Sedgwick et al., 2006; Westbye et al., 2008). 
Alternatively, increased mutant frequency could result from unrepaired lesions that undergo 
mutagenic bypass (Nay et al., 2012). In murine models, targeted deletion of Alkbh1 is linked to 
developmental defects with Alkbh1 enzymatic activity primarily directed at demethylation of 
histone H2A (Nordstrand et al., 2012; Ougland et al., 2012; Pan et al., 2008). However, because 
this thesis is focused on DNA repair, our discussion of ALKBH1 will be limited. Similarly, 
although FTO removes 1-meA and 3-meC damage in vitro, its role is more closely linked to 
functions in RNA demethylation or demethylation of 6-meA (Hwang et al., 2009), which is not 
usually connected to DNA repair functions, and will therefore not be discussed further. 
 
3.1. ALKBH protein structure/active site organization 
 
 Although sequence homology is limited to active site and conserved domains in human 
ALKBH proteins, the secondary structures are conserved. For instance, all ALKBH family 
proteins have similar catalytic domains, but varying DNA recognition motifs (Sundheim et al., 
2008). Conserved domains in the FeKGD superfamily include a jelly-roll topology with a His2-X-
Asp/Glu-Xn-His2 motif (Sundheim et al., 2006). Specifically, the jelly-roll is made up of two 
sheets of antiparallel β-strands that contain His131, Asp133, and Trp69 residues which bind the 
iron and 2-oxoglutarate co-substrates (Sundheim et al., 2006; Westbye et al., 2008; Yang et al., 
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2008) (Figure 5). Additionally, the His187 residue of the jelly-roll assists in Fe ligation, whereas 
Arg204 and Arg210 act to form salt bridges with the carboxylates of 2-oxoglutarate (Yu et al., 
2006). 
 
The catalytic core of both ALKBH2 and ALKBH3 is made up of three major 
components: a double-stranded β-helix, a nucleotide recognition lid, and an N-terminal extension 
(Yi et al., 2009; Yu et al., 2006). The Nucleotide Recognition Lid (NRL) is comprised of β-
hairpin motifs which create a substrate binding groove that covers the active site until substrate is 
bound (Sundheim et al., 2006). Despite similar catalytic mechanisms, β-strands and α-helices that 
create distinct outer walls of the DNA binding groove, which is involved in substrate recognition 
	  
Figure 5. Structures of ALKBH2 (PDBid: 3S57) and ALKBH3 ((PDBid: 2IUW). (A) ALKBH2 
structure without bound DNA [113]. The space filling yellow Mn(II) was substituted to block 
catalytic activity, but is normally occupied by an Fe(II). (B) ALKBH3 structure without bound DNA. 
The Fe(II) is shown as space filling in green [112]. (C) ALKBH2 with bound DNA in two 
orientations along the z axis of the DNA (left) and along the y axis of the DNA. 
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and specificity, vary between ALKBH proteins (Aas et al., 2003). More explicitly, this 
divergence is present in the two looped structures, or “flips” that lie between the single β-sheet 
and two α-helices in the N-terminal portion of the catalytic region (Sundheim et al., 2006; Yang 
et al., 2008). In ALKBH2, the first flip is made up of 20 residues that constitute a β-hairpin and a 
short α-helix that together create a hydrophobic substrate binding groove (Yang et al., 2008; Yi et 
al., 2012). ALKBH3, on the other hand, contains a first flip that is a β-hairpin that is made up of 
only 17 residues, forming a hydrophilic binding groove that has a preference for single stranded 
DNA or RNA substrates (Sundheim et al., 2008; Sundheim et al., 2006). The second flip in 
ALKBH2 consists of 24 residues that is composed of three b-sheets, allowing for interaction with 
both strands of DNA, whereas flip 2 of ALKBH3 is only 12 residues long and is made up of a 
single β-sheet (Sundheim et al., 2008). 
 
To facilitate repair, ALKBH proteins flip the damaged base into their active site enabling 
the protein to interact with both strands of the DNA (Sundheim et al., 2008; Yang et al., 2008). In 
the case of ALKBH2, a short loop with a positively charged RKK sequence (Arg241–Lys243) is 
involved in grasping the complementary strand of the DNA, while a longer, more flexible loop, 
containing the residues Arg198, Gly204 and Lys205, binds the opposite DNA strand (Sundheim 
et al., 2008; Yang et al., 2008; Yu et al., 2006). Additionally, ALKBH2 uses an aromatic finger 
residue, Phe102, to intercalate within the duplex stack, filling the gap resulting from DNA base 
flipping (Yang et al., 2008). Tyr76 forms hydrogen bonds with the two phosphates 5′ of the 
methylated base, maintaining the substrate within the active site and residues Asp135 and Glu136 
hydrogen bond with the exocyclic amino group via a water molecule (Yang et al., 2008; Yi et al., 
2009). On the contrary, ALKBH3 does not contain the same aromatic finger residue and RKK 
motif as ALKBH2 and therefore has a greater preference for single-stranded DNA substrates. As 
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a result, “flipping” of the damaged base is accomplished by squeezing the DNA proximal to the 
damage, causing it to rotate outward (Sundheim et al., 2006; Yang et al., 2008). Though the 
structures of the ALKBH homologs 4 – 8 have not been studied extensively, differences in the 
organization of the catalytic residues and active sites are predicted to influence the substrate 
specificities as well as enzymatic activities of these homologs (Sedgwick et al., 2006). 
 
3.2. Substrate recognition/repair mechanism 
 
 The ALKBH family of proteins removes and repairs DNA methyl adducts via a 
mechanism known as oxidative demethylation which results in the direct restoration of the 
original base coupled with the release of the hydroxylated methyl group as formaldehyde (Figure 
6) (Aas et al., 2003; Falnes et al., 2002; Trewick et al., 2002). Other modifications can also be 
removed using similar mechanisms. Unlike MGMT, the repair mechanism utilized by the 
ALKBH family requires molecular oxygen, Fe(II), and α-ketoglutarate as co-factors to execute 
removal of alkyl adducts from DNA (Aas et al., 2003; Falnes et al., 2002).The ALKBH repair 
	  
Figure 6. Products and intermediates formed during oxidative dealkylation of methyl, etheno, 
and exocyclic bases. (A) Repair of 1-meA results in release of formaldehyde, (B) 1-ethylA adducts 
release acetaldehyde, (C) 5 membered ring cyclized adduct (ethenoA, eA) releases diacetaldehyde, 
and (D) the 6 membered ring cyclized adduct (a-hydroxypropano-dG) releases malondialdehyde. 
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reaction consists of four steps with various intermediates (Liu et al., 2009). The first step of this 
mechanism involves a reaction between the active site Fe(II) and O2 which produces a superoxo 
anion (O2- ) bound to Fe(III) (Mishina and He, 2006). The superoxide attacks the α-keto carbon of 
the α-ketoglutarate, resulting in a bridged peroxotype intermediate (Mishina and He, 2006). The 
α-ketoglutarate intermediate is decarboxylated releasing succinate and CO2 and undergoes a 
heterolytic cleavage of the O–O bond to form the high-valence ferryl-oxo intermediate. This 
intermediate then hydroxylates the alkyl adduct on the DNA producing an unstable intermediate 
that decomposes in water, with release of formaldehyde for methylated bases (and other 
aldehydes, depending on the substrate) restoring the original undamaged base (Figure 6) 
(Bleijlevens et al., 2008; Mishina and He, 2006; Ringvoll et al., 2006; Sedgwick et al., 2006).  
 
Though ALKBH proteins primarily repair 1-meA and 3-meC (Figure 4A), those proteins 
also repair etheno and other exocyclic bases, though to a lesser extent than the methylated bases 
(Figure 4B and 4C, Figure 6C and 6D) (Delaney and Essigmann, 2004; Falnes, 2004; Falnes et 
al., 2004; Frick et al., 2007; Mishina and He, 2006; Ringvoll et al., 2006). 
 
3.3. Gene expression/protein regulation 
 
ALKBH2 and ALKBH3 are located on chromosomes 12q24 and 11p11, respectively and 
are considered housekeeping genes. The mRNA and protein levels of the ALKBH2 and 3 
mRNAs vary with tissue type and the homolog (Duncan et al., 2002; Lee et al., 2005; Tsujikawa 
et al., 2007). However, both ALKBH2 and ALKBH3 are highly expressed in the testis and ovary 
(Lee et al., 2005; Tsujikawa et al., 2007). ALKBH2 and ALKBH3 contain CpG islands in their 
promoters (Figure 7A and 7C), but the role that those structures play in gene expression remains 
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undefined. 
Control of expression for ALKBH2 and ALKBH3 has not been as thoroughly studied as 
for MGMT. Interestingly, the arrangements of the ALKBH2 and uracil-DNA glycosylase gene 
(UNG) suggest a possible manner to control gene expression. ALKBH2 is adjacent to UNG on 
human chromosome 12, but transcribed in the opposite direction (Krokan et al., 2004). The 
opposite orientations of these two genes could have an influence on their expression (Figure 7B). 
For ALKBH3, expression could be controlled by a putative ALKBH3 antisense RNA that is also 
converted into a long non-coding RNA sequence (Figure 7D). The role that the lncRNA plays in 
ALKBH3 expression remains to be established. Unlike MGMT, control of ALKBH2, and 
ALKBH3 expression via micro RNAs has not been examined. However, the mir-505-5p miRNA 
is reported to target ALKBH2 (www.Exiqon.com), whereas at least 3 miRNAs (mir-188-3p, mir-
4774-3p, and miR5580-5p) that could be involved in regulating ALKBH3 expression have been 
identified. Thus, the regulation of ALKBH2 and ALKBH3 expression has much that is yet 
 
Figure 7. Promoter CpG islands, gene structure and major mRNAs for ALKBH2 and ALKBH3. 
(A) ALKBH2 promoter region. CpG islands are boxed with individual CpG sequences as vertical 
lines. Numbers at the top refer to nucleotide distances from mRNA start sites (+1). The gene is the 
yellow box and the chromosomes are indicated on the left hand side of the figure. CpG islands were 
identified using Methprimer (http://www.urogene.org/cgi-bin/methprimer/methprimer.cgi). (B) 
ALKBH2 showing the position and size of the uracil-DNA glycosylase gene (UNG). Exons are 
indicated in red and the gene in brown. (C) ALKBH3 promoter region. The CpG island and gene 
sequences are as for part A (D) ALKBH3 and the position of the antisense ALKBH3-AS1 are shown in 
purple for the unspliced antisense-RNA and in blue for the spliced lncRNA. The exons for the 
mRNA are indicated in red. 	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unresolved. 
 
3.4. Protein localization 
 
ALKBH2 and ALKBH3 not only have different substrate preferences, but also exhibit 
different subcellular localization patterns, suggesting distinct biological functions. ALKBH2 is 
strictly nuclear and is found mainly at replication foci during S-phase (Duncan et al., 2002; Lee et 
al., 2005; Tsujikawa et al., 2007). Additionally, ALKBH2 co-localizes with PCNA (Lee et al., 
2005; Tsujikawa et al., 2007), indicating a possible role in DNA repair close to the replication 
fork. In contrast, ALKBH3 is found in the nucleus and in the cytoplasm (Duncan et al., 2002; 
Sundheim et al., 2008). Association of ALKBH3 with the activating signal cointegrator complex 
3 (ASCC3) helicase enzyme is consistent with nuclear localization (Dango et al., 2011), whereas 
the role of ALKBH3 in mRNA repair is consistent with its localization in the cytoplasm (Lee et 
al., 2005). 
  
3.5. Post-translational modifications of ALKBH proteins 
 
Post-translational modifications of residues within ALKBH2 and ALKBH3 have been 
examined using site-specific mutagenesis methods, as well as mass spectrometry (Hornbeck et 
al., 2012), but the effects of these modifications are unknown. ALKBH2 residues Lys34 and 
Lys104 can be acetylated, Tyr91 and Thr93 and Thr252 can be phosphorylated, and Lys104 can 
be ubiquitinated (Hornbeck et al., 2012). Though the effects of these modifications on ALKBH2 
activity have not been established, it is important to note that residue Lys104 falls within the 
variable region of the N-terminus which provides for protein specificity. Similarly, post-
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translational modification of ALKBH3 includes several phosphorylated residues such as Thr126, 
Thr212, and Thr214, as well as Tyr127 and Tyr143, some of which have been shown to correlate 
with acute myelogenous, chronic myelogenous, and T-cell leukemia (Hornbeck et al., 2012). 
Moreover, phosphorylation of active site residues Thr212 and Thr214 have been observed in liver 
cancer tissue samples, while phosphorylated Tyr residues have been reported in lung and non-
small cell lung cancer cell lines (Hornbeck et al., 2012). Despite some intriguing results as 
possible biomarkers for tumors, the functions of these post-translation modifications have not 
been identified. 
 
3.6. Biological significance of direct repair by ALKBH proteins 
 
The presence of ALKBH2 and/or ALKBH3 reduces cell cytotoxicity and mutagenicity, 
as shown in Alkbh-deficient murine models treated with SN2 alkylating agent methyl 
methanesulfonate (MMS) (Calvo et al., 2012; Hornbeck et al., 2012; Nay et al., 2012). Though 
the major damage sites repaired by ALKBH proteins are only susceptible to modification when 
DNA is single-stranded, formation of 1-meA and 3-meC at DNA base-pairing positions prevents 
proper base insertion which can halt DNA synthesis (Delaney and Essigmann, 2004), causing 
replication fork collapse (Andreassen et al., 2006). As a result, persistence of 1-meA and 3-meC 
adducts increases cell cytotoxicity by triggering programmed cell death (Calvo et al., 2012; 
Hornbeck et al., 2012; Nay et al., 2012). In contrast to O6-meG, following alkylation of the N1 of 
a purine or the N3 of pyrimidine, only a single hydrogen bond can be readily formed. Therefore, 
increased mutant frequency exhibited in Alkbh-deficient murine models is likely due to adduct 
bypass by TLS DNA polymerases (Furrer and van Loon, 2014). In E. coli, evaluation of 1-meA, 
3-meC, 1-meG, or 3-meT mutagenicity revealed that all adducts were highly mutagenic, with the 
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exception of 1-meA, which was only slightly mutagenic (Delaney and Essigmann, 2004). 
Interestingly, of the adducts repaired by ALKBH proteins, 3-meC is formed at the highest 
frequency in response to MMS treatment (Table 1) and the mutations identified following MMS 
treatment in Alkbh2- or Alkbh3-deficient primary MEFs were C:G ! A:T and C:G ! T:A 
(Vittal et al., 2004), suggesting that 3-meC is highly mutagenic in absence of repair.  
 
Direct repair by ALKBH proteins has a biological significance that is not well 
understood. Varying expression levels of ALKBH2 and ALKBH3 also contribute to the 
progression or suppression of different types of cancers. Down-regulation of ALKBH2 increases 
sensitivity of H1299 lung cancer cells to the drug, cisplatin, improving overall survival (Wu et al., 
2011). However, down-regulation of ALKBH2 has been observed to promote the growth of 
gastric cancer cells (Wu et al., 2011). Mutations in ALKBH2 and ALKBH3 have also been 
associated with their enhanced expression levels in glioma cells and pediatric brain tumors 
(Cetica et al., 2009; Lee et al., 2010). ALKBH2 also mediates resistance to the alkylating agent 
therapeutic temolozomide (TMZ) in glioblastoma cells (Johannessen et al., 2013). ALKBH3 
silencing induced senescence and increased sensitivity to alkylating agent therapies in prostate 
cancer cells (Dango et al., 2011; Wu et al., 2011). Therefore, further investigation of the roles of 
ALKBH2 and ALKBH3 in different types of cancer is important to define the specific roles of 
individual ALKBH family proteins.  
 
4. Models of direct reversal repair and implications as therapeutic targets 
 
Repair of DNA damage is critical for cell survival and maintenance of genome integrity. 
Not surprisingly, cells depend on direct repair mechanisms to remove damage that could 
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otherwise be cytotoxic or mutagenic (Drablos et al., 2004). Understanding the roles that direct 
reversal repair proteins play in genome stability also enables exploration and exploitation of these 
proteins in regard to therapeutics. Therefore, use of currently established animal models, as well 
as generation of additional models is integral in development of diagnostic and therapeutic 
approaches.  
 
4.1. Current mammalian models defective in DNA direct reversal repair genes 
 
The effects and efficiency of repair pathways is best studied by observing the effects on 
cell cytotoxicity, replication, transcription, and mutation in the absence of the repair proteins. To 
evaluate the impact of the absence of direct repair proteins animal models with targeted deletions 
have been developed ALKBH proteins. Interestingly, murine knock-out (KO) models for Alkhb2 
or Alkbh3 do not exhibit a detectable phenotype in the absence of alkylating agent treatment 
(Calvo et al., 2012; Feng et al., 2014; Nay et al., 2012; Ringvoll et al., 2006; Sekiguchi and 
Sakumi, 1997; Vittal et al., 2004). Even though Alkbh2- and Alkbh3-deficient murine models do 
not show any overt phenotypic changes compared to their wild type counterparts, over time the 
Alkbh2-deficient mice accumulate high levels of 1-meA in the liver (Ringvoll et al., 2006). 
Similarly, double mutants with targeted deletions in both Alkbh2 and Alkbh3 do not demonstrate 
an obvious phenotype and the mice are fertile and live to normal ages (Calvo et al., 2012; Nay et 
al., 2012; Ringvoll et al., 2006). Of note, a mouse model that targeted both the FeKGDs (Alkbh2 
and Alkbh3) and the base excision repair pathway (Mpg or Aag) was generated. All of those 
proteins have roles in repair of alkylation damage. In response to alkylation damage (chemically-
induced colitis), that mouse model deficient in all three proteins manifested a synergistic 
phenotype that resulted in death with even a single treatment (Calvo et al., 2012). Due to the lack 
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of phenotypic effect and limitations treating animals, analysis of the effects of Alkbh2 and/or 
Alkbh3 deficiency have also been conducted using primary and immortalized mouse embryonic 
fibroblasts (MEFs) (Calvo et al., 2012; Nay et al., 2012; Ringvoll et al., 2006). 
 
4.2. Generation of new in vitro mammalian models defective in DNA direct reversal repair 
genes 
  
 The capacities to directly target human cells to either abrogate protein function or place 
specific tags on proteins have been limited. Recently, the development of clustered regularly 
interspaced short palindromic repeats/CRISPR associated endonuclease 9 (CRISPR/Cas9) 
technologies has permitted the generation of targeted deletions in human and rodent cells rapidly. 
Implementation of that technology will facilitate the study of DNA repair and mutagenesis in 
great depth. The basis for targeting genomic DNA to generate deletions is outlined (Figure 8). A 
guide RNA is designed based on an exon sequence in the genomic DNA. Following transfection 
	  
Figure 8. Outline of CRISPR/Cas9 modification of genomic DNA. Structure of the Cas9 complex is 
from Nishimasu et al. [147]. The guide RNA is represented by black in the structure, the target DNA 
by gold, helical regions by cyan, and b-sheets by red. The cell cytoplasm is represented in blue and the 
nucleus in light blue. The target region in genomic DNA is in red. The figure was adapted from Pennisi 
(Pennisi, 2013). 
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of a plasmid expressing the guide RNA and the Cas9 mRNA, the protein-RNA complex will 
induce a double strand break in the genomic DNA. Repair by non-homologous end-joining leads 
to a change in the reading frame that inactivates the protein. This powerful technology can also be 
used to introduce point mutations and to create other cancer prone models in human cells for 
study in vitro and also in vivo in animal models. Readers are referred to recent publications that 
describe the possibilities of using these methods (Hsu et al., 2014; Platt et al., 2014; Sternberg et 
al., 2014). This project took advantage of this recent technology to inactivate the Alkbh2 and 
Alkbh3 genes in mammalian skin fibroblasts as will be discussed later. 
 
4.3. Direct repair proteins as therapeutic targets 
 
DNA repair deficiency is associated with increased cancer risk and formation of tumors, 
but has also been used in therapeutic strategies employing synthetic lethality in an effort to 
overload the cancer cells with damage that results in apoptosis while normal cells with efficient 
repair can eliminate the damage invoked by the chemotherapeutic regimen (Abbotts et al., 2014; 
Curtin, 2013; Furgason and Bahassi el, 2013; Postel-Vinay et al., 2012; Soncini et al., 2012). 
Commonly anti-neoplastic therapies utilize alkylating agents as well as ionizing radiation (IR); 
however, these treatments not only induce cell death in cancer cells, but can also increase the 
formation of mutations in normal cells, leading to an increased risk of secondary cancers. 
Synthetic lethality for DNA repair agents exploits defects in DNA repair found in tumor cells that 
use alternative repair systems for repair. Inhibiting the alternative repair systems results in 
increased tumor cell death specifically targeted to the tumors. Currently, both chemotherapy and 
radiation are used in combination to target specific DNA repair proteins in cancer cells in order to 
improve therapeutic efficacy and limit drug resistance (Kelley and Fishel, 2008; Sanchez-Perez, 
	   22	  
2006). One of the advantages of direct reversal repair proteins is that a single protein is ultimately 
responsible for elimination of the damage and that no breaks are made in the DNA by the repair 
mechanism. Targeting direct reversal repair proteins to increase sensitivity could supplement the 
efficacy of the alkylating agents already used in clinical protocols. 
 
The roles of ALKBH2 and ALKBH3 in response to methylating agent chemotherapies 
(particularly for TMZ) remain unclear. Although MGMT is associated with resistance, there are 
reports of ALKBH2 also enhancing resistance (Johannessen et al., 2013). Inhibitors of Alkb have 
already been identified, but inhibitors of the human homologs have not been reported 
(Karkhanina et al., 2009; Welford et al., 2003; Woon et al., 2012). The identification of ALKBH 
inhibitors and their use with current chemotherapeutics could provide new tailored therapies for 
patients. 
 
In addition to the development of targeted therapies, RNA interference-mediated gene 
silencing (RNAi) (Lakomy et al., 2011) is a possible alternative approach for specifically 
targeting ALKBH family members that allows depletion of proteins for extended periods of time. 
Lowering protein levels of species that protect against DNA damage would render cells more 
susceptible to chemotherapeutic agents and should theoretically offer better drug efficacy.  
 
siRNAs can be identified using empirical methods to target direct DNA repair protein 
mRNAs (i.e., for ALKBH2 or ALKBH3). Rather than using siRNA constructs defined 
empirically, naturally occurring miRNAs could be used to reduce DNA repair protein levels and 
improve therapeutic responses for tumors (e.g., glioblastomas) that respond to methylating agents 
(e.g., TMZ). miRNAs associated with ALKBH2 and 3, such as mir-505-5p miRNA for ALKBH2 
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(www.Exiqon.com) and mir-188-3p, mir-4774-3p, and miR5580-5p for ALKBH3, could be used 
as new therapeutic avenues, because there are reports that TMZ response is linked to the presence 
of ALKBH2 or ALKBH3 (Dango et al., 2011; Johannessen et al., 2013; Nay et al., 2012). The 
use of miRNAs has great potential for high specificity with limited side effects. Targeting 
transcripts using miRNAs is an exciting area for developing new therapeutic targets and 
biomarkers for predicting outcomes. Employing miRNAs could have substantial benefits for 
patients, but much work remains to bring such promising therapies to fruition. 
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SPECIFIC AIMS 
 
In order to investigate the biological roles of the direct reversal repair proteins, ALKBH2 and 
ALKBH3 in telomerase immortalized human skin fibroblasts, we will:  
1) Generate cell lines deficient in the ALKBH2 and ALKBH3 genes using CRISPR/Cas9 
targeting of those genes. 
2) Isolate individual clones of transfected cells, isolate DNA from each clone, PCR amplify 
the DNA, and perform fragment analysis to assess targeting of ALKBH2 or ALKBH3 
alleles. 
3) Expand clones in which the targeted ALKBH2 and/or ALKBH3 genes have disrupted open 
reading frames. 
4) Determine the ALKBH2 and ALKBH3 enzymatic activities in crude extracts of cells 
with the disrupted reading frames using substrates for disrupted ALKBH2 and ALKBH3. 
5) Analyze the sensitivity of the disrupted ALKBH2 and ALKBH3 targeted clones to a 
methylating agent using a survival assay. 
 
We expect these results will show: 
1) Cells deficient in either ALKBH2 and/or ALKBH3 will have aberrant DNA repair and 
thus, will be significantly more sensitive to alkylating agent treatment than wild type 
controls. 
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METHODS 
 
This study sought to investigate the biological roles of direct reversal repair proteins, 
ALKBH2 and ALKBH3 in mammalian cells. In order to accomplish that, the levels of adduct 
accumulation, alkylating agent sensitivity, and spontaneous and alkylating agent-induced 
mutagenesis also had to be evaluated within the cells.  
 
Cell lines and Targeting Vectors 
Cell lines deficient in these proteins were generated. Human skin fibroblasts were 
originally obtained as circumcised male infant foreskins as discard material from the Arcadia 
Methodist Hospital in 1995 using an Institutional Review Board protocol. One of the primary cell 
lines arising from those cells designated HF57 was transfected with a human telomerase cDNA 
expression vector to immortalize the skin fibroblasts and is designated as the HTERTG cell line. 
These HTERTG cells are karyotypically normal (46 chromosomes) and were maintained in 
culture with serial passaging until ready for transfection.  
 
CRISPR/Cas9 Targeting Vectors 
Cells with the knockout ALKBH2 and ALKBH3 genes were generated using targeting 
vectors prepared by the CRISPR/Cas9 system using an RNA-guided gene to disrupt and cause 
double-stranded breaks in the DNA sequence around the sequence for those alleles (Figure 8). 
The targeting vectors (Table 2) were incorporated into the pX330 plasmid using restriction digest 
enzyme BbsI to cut the sequence and insert the vector (Figure 9-10). Individual clones were 
grown and transferred to smaller plates to expand in duplicates. DNA was isolated from each 
clone and analyzed using PCR and fragment analysis. If fragment analysis indicated a change in 
the number of base pairs with respect to the wild type HTERTG control, further analysis was 
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done on that clone to determine what change in the sequence occurred as a result of transfecting 
the cells. 
Table 2. ALKBH2 and ALKBH3 CRISPR-Cas9 targeting sequences. Targeting vectors were 
designed using the CRISPR Design Tool identifying PAM sequence (5’-NGG or 5’-NAG) within 
the respective genomes. 
 
CRISPR-Cas9 Targeting Sequences 
ALKBH2 TOP (Exon 2) GCCCGAATGTGCCGCCAGCTAGG 
ALKBH2 BOTTOM (Exon 2) GGGCTCAAGGGGGCCTTTTGAGG 
ALKBH3 TOP (Exon 5)  GAAAGAAGCTGACTGGATATTGG 
ALKBH3 BOTTOM (Exon 7) GTGATGATGAACCCTCACTAGGG 
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Figure 9. Vector maps of 
pX330 plasmid with 
incorporated ALKBH2 
CRISPR/Cas9 targeting 
vector. Sequences used to 
target the ALKBH2 
alleles were generated 
using the CRISPR/Cas9 
system. pX330 plasmids 
were cut at the BbsI 
restriction sites and 
targeting sequences were 
inserted as shown. Vector 
maps were created using 
SnapGeneTM. 	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Figure 10. Vector maps 
of pX330 plasmid with 
incorporated ALKBH3 
CRISPR/Cas9 targeting 
vector. Sequences used 
to target the ALKBH3 
alleles were generated 
using the CRISPR/Cas9 
system. pX330 plasmids 
were cut at the BbsI 
restriction sites and 
targeting sequences were 
inserted as shown. Vector 
maps were created using 
SnapGeneTM. 	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Cell Culture 
HTERTG (ATCC human telomerase reverse transcriptase immortalized human skin 
fibroblasts) cells were maintained in culture (1X Dulbecco’s Modified Eagle Medium [DMEM], 
10% Fetal Bovine Serum [FBS], 1% L-glutamine) and serially passaged in a 1:3 ratio when 70-
80% confluence was reached. Cells were washed three times with 0.22 µm filter-sterilized 10mM 
PBS (Phosphate buffered saline), trypsinized (0.06% Trypsin-EDTA) at 37°C for four minutes, 
centrifuged at 3,000 rpm for five minutes, and resuspended in medium before being plated. Cells 
were grown without antibiotics at 37°C at ~5% CO2. 
 
CRISPR-Cas9 targeting vector design 
To target specific sequences corresponding to ALKBH2 and ALKBH3 within the 
genome, the CRISPR-Cas9 system was used. The Streptococcus pyogenes Cas9 targets 20 
nucleotide DNA sequences that are followed by a 5’-NGG or 5’-NAG PAM sequence, while 
avoiding any non-specific off-target modifications. This ensures targeting of just that specific 
sequence. The DNA sequence from exons within the ALKBH2 and ALKBH3 genome were used 
as input on the CRISPR Design Tool. PAM sequences were identified within the input sequences 
and 20 nucleotide output sequences were returned with scores ranking target sites based on 
predicted specificity. This is determined by an algorithm based on specificity analysis found in a 
2013 study (Hsu et al., 2013). The output sequence with the highest score was chosen as the 
targeting site for each genome and was then isolated and inserted into the pX330 plasmid to be 
used for transfection. 
 
	   30	  
 
Transfection of HTERTG fibroblasts 
HTERTG fibroblasts were transfected with endotoxin-free CRISPR-Cas9 constructs that 
target the ALKBH2 and ALKBH3 genes independently. Cells were nucleofected when 
confluency reached 80-90%. The Amaxa 4-D nucleofector device (FF-113 program) was used 
nucleofect the cells (Lonza #AAF-1002B, #AAF-1002X). To prepare transfection complexes for 
transfection of 200,000 cells, 400 ng of endotoxin-free plasmid DNA was added to a well in an 
electrocuvette strip (Lonza). The nucleofection solution (P2 Primary cell kit solution + 
supplement, Lonza #V4XP-2032) was prepared. As a positive control to visualize transfection 
efficiency, 400 ng of endotoxin-free plasmid DNA was mixed with 400 ng of pmaxGFP (Lonza 
#V4XP-2032) and added to a well in an electrocuvette strip (Lonza). HTERTG cells were washed 
three times with 10mM PBS, trypsinized and counted. 250,000 cells were transferred to each of 
two 2ml sterile microcentrifuge tubes. Cells were centrifuged for ten minutes at 90g and then 
resuspended in 20µl of nucleofection solution prepared earlier. 20µl of resuspended cells were 
added to each well containing the plasmid DNA and mixed by pipetting up and down several 
times. Cells were then nucleofected using the FF-113 program, maintained at room temperature 
for 10 minutes after nucleofection, recovered in 80µl of medium, and then transferred to a 60mm 
cell culture plate containing a 1:1 mixture of regular medium:conditioned medium that was pre-
warmed. Cells from the first plate were serially diluted 10-fold into three more successive plates 
and placed at 37°C and 5% CO2. Transfection efficiency was estimated using fluorescence 
microscopy after 24 hours. This transfection step was performed a second time on the initially 
transfected cells to increase the likelihood of targeting both alleles. 
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Isolation of HTERTG clones 
Tranfected cells were maintained in culture (50% conditioned medium, 50% 1X 
DMEM+10% FBS) and passaged depending on growth of the individual colonies. When 
visualized under a microscope, individual colonies of cells that were distanced from each other 
were demarcated and individually passaged into single wells in flat-bottom 4-well plates 
(NunclonTM Surface #D6789-1CS). Clones were expanded into two separate wells for duplicates 
and then each well was expanded into 30mm plates. When 70-80% confluence was reached, cells 
from one plate were washed, trypsinized, and 90% were frozen in 500µl of freezing medium 
(90% FBS, 10% DMSO) at -80°C and the remaining 10% were replated to ensure no 
contamination was present in the freeze. Cells from the duplicate plate were washed and their 
DNA was isolated using a NaCl gDNA extraction method. 
 
NaCl gDNA extraction for HTERTG clones 
Cells were washed twice with 1ml of 1X PBS. Fresh lysis buffer was prepared on ice (1M Tris 
pH 8.0, 0.5 M EDTA pH 8.0, 5M NaCl, 20% SDS, 20 mg/ml proteinase K, 10 mg/ml RNAse A, 
and ddH2O). 400µl of lysis solution was added to each 30mm plate and cells were collected from 
the plate with a sterilized cell-scraper and transferred into a sterile 2ml microcentrifuge tube. 
Cells were incubated in lysis solution at 37°C for at least three hours. 200µl of saturated NaCl 
was added to each tube, vortexed for 15 seconds until foamy, and incubated at 56°C for 10 
minutes. Cells were centrifuged at 5000g at 4°C for 30 minutes and the supernatant which 
contained the gDNA was centrifuged again to remove all cell debris. 2.3 volumes of ice cold 
100% ethanol was added and tube was inverted to mix thoroughly and then placed at -20°C to 
allow precipitation of gDNA. Each tube was then centrifuged at 17,000g for 15 minutes at 4°C 
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and supernatant was removed. The gDNA pellet was then washed with 500µl of 70% EtOH and 
centrifuged again at 17,000g for five minutes at room temperature. Supernatant was discarded 
and pellet was allowed to air-dry briefly. gDNA was resuspended in ~30µl of 10mM Tris pH 8.0 
and the concentration was determined based on the absorbance at 260nm using a NanodropTM 
ND-1000 spectrophotometer. 
 
Amplification of ALKBH2/ALKBH3 DNA fragment from HTERTG clones 
To determine whether transfected cells targeted either one or both alleles, regions of 
DNA from each clone were amplified with respect to the CRISPR/Cas9 targeting site. PCR 
primers were designed to include the regions within the targeted exons. Fragment analysis which 
was performed on the PCR products allows for visualization of changes in fragment size of the 
region of DNA that was amplified from each clone. The protocol used for this study was adapted 
from a study done in 2000 (Schuelke, 2000)(Figure 11). An M13(-21) tag on the forward primer 
is used to adapt a universal FAM (Fluorescein amidite) dye primer ODN to any PCR amplified 
sequence to permit visualization with an automatic sequencing instrument. When designing 
primers, the M13(-21) sequence was added to the 5’-end of forward primers for ALKBH2 and 
ALKBH3, as the FAM dye binds to the 5’-end of a nucleic acid. 
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50ng of DNA from each clone was used in the PCR reaction and all reactions were 
performed in a 50µl reaction. Primer sequences at 10µM were used as follows:  
ALKBH2 forward: CCTTCCGGCTTTAACATCTTCT; M13(-21) ALKBH2 forward: 
TGTAAAACGACGGCCAGTCCTTCCGGCTTTAACATCTTCT; ALKBH2 reverse: 
GCCTCTTCCTTGTGCTTTCT; ALKBH3 forward: CCCTCACCTATCATCCCTTTATC; 
M13(-21) ALKBH3 forward: 
TGTAAAACGACGGCCAGTCCCTCACCTATCATCCCTTTATC; ALKBH3 reverse: 
	  
	  	  
Figure 11. PCR amplification pathway to incorporate FAM label onto targeted amplified 
sequence. A) A forward primer was designed and used to include the regions within the targeted 
exon with an M13(-21) sequence added to the 5’-end. B) A reverse primer was designed and used to 
include regions within the targeted exon. C) FAM dye binds to the 5’-end of M13(-21) sequence on 
forward primer. D) In the first PCR cycles the M13(-21) tail is incorporated into PCR products at an 
annealing temperature of 58°C. E) In the final seven cycles of the reaction, the annealing temperature 
is lowered to 53°C, optimal for incorporation of the FAM label. F) The final FAM-labeled amplified 
product can be observed and analyzed on a laser detection system for fragment analysis. Image 
adapted from (Schuelke, 2000). 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
Figure 10. PCR amplification pathway to incorporate FAM label onto targeted amplified sequence. 
A) A forward primer was designed and used to include the regions within the targeted exon with an 
M13(-21) sequence added to the 5’-end. B) A reverse primer was designed and used to include 
regions within the targeted exon. C) FAM dye binds to the 5’-end of M13(-21) sequence on forward 
	   34	  
CCTTGAACTCTCACCTCTATCC. PCR was performed by initial denaturation at 95°C for 
3 min, followed by 29 cycles of 15 s at 95°C, 15 s at 58°C and 45 s at 72°C. After the initial 30 
cycles were complete, an addition seven cycles were performed at a lower annealing temperature 
to allow for the FAM label to be integrated into the top strand of each copy. These last seven 
cycles followed 15 s at 95°C, 15 s at 53°C, and 45 s at 72°C, followed by a 30 minute extension 
at 72°C. PCR using wild type HTERTG DNA was used as a negative control. MyTaq DNA 
polymerase (Bioline #BIO-21105) and 5X MyTaq buffer (Bioline #BIO-25041) were used in the 
PCR reactions using a BioRad S1000TM Thermal Cycler. 
10µl of the PCR products were run on a 1% agarose gel in 1X (Tris-base, acetic acid, EDTA), 
stained with ethidium bromide (EtBr) in 1X TAE, and visualized using a BioRad ChemiDocTM 
MP Imaging System to confirm the amplification was successful. 
 
Fragment Analysis of HTERTG ALKBH2 or ALKBH3 clone PCR products 
10µl of the FAM-labeled PCR products from ALKBH2 and ALKBH3 clones analyzed by 
the Integrated Genomics Core facility at the City of Hope Beckman Research Institute. ALKBH2 
fragments were expected to be 324 bp and the ALKBH3 fragments, 615 bp. A 500 bp LIZ size 
standard was used as a marker (Applied Biosystems #4322682) and 2µl were loaded for 
ALKBH2 PCR products and 5µl for ALKBH3 PCR products. Fragment analysis results were 
analyzed using the PeakScanner software. 
 
Sequencing of HTERTG ALKBH2 and ALKBH3 clones 
To confirm the targeting and verify disruption of the open reading frame, sequencing of 
the DNA from the targeted cells is required. PCR reactions using the forward and reverse 
primers, without the M13(-21) tag, were performed on the gDNA extracted from respective 
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clones. 2µl of the PCR product was ligated at 4°C for two hours into a pENQUIS-TA 
((http://lade.udec.cl/wp-content/uploads/LADE-pENQUISTA.pdf)) vector with a 2X Ligation 
Master Mix (Qiagen #231224) and then transformed into Qiagen EZ Competent Cells from the 
Qiagen PCR CloningPLUS Kit (Qiagen #231224), recovered in 250µl of SOC and selected on LB-
agar plates with ampicillin (100 ng/ul). Cells were grown overnight at 37°C. Individual colonies 
were selected and plasmids were isolated using the Qiagen Spin Miniprep kit (Qiagen #27106). 
Isolated plasmids of each colony were then sent to the Integrated Genomics Core Facility at the 
City of Hope Beckman Research Institute for DNA sequencing using [BigDye V3.1 chemistry]. 
 
Purification of ALKBH2 and ALKBH3 proteins  
His-tagged ALKBH2 and ALKBH3 sequences were ligated into the pET28a(+) bacterial plasmid 
that includes the T7 promoter (Figure 12).  
	  	  
Figure 12. ALKBH2 and ALKBH3 expression vectors. His-tagged A) ALKBH2 and B) ALKBH3 
sequences were ligated into the pET28a (+) bacterial plasmid which includes the T7 promoter. These 
vectors were used to express His-tagged ALKBH2 and ALKBH3 protein in Rosetta(DE3)pLysS 
cells. 	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These expression vectors were then transformed into Rosetta™(DE3)pLysS competent cells 
(Novagen #70956-4), plated onto LB-Agar plates with kanamycin (15 μg/ml), and grown overnight at 
37°C. A single colony from the plate was grown in 5 mL of LB overnight and 2.5 mL of cells were grown 
up into 50 mL of LB with (15 µg/ml). When cells reached an OD600 of 0.5, they were induced with 50µl of 
1M IPTG. 1.5 hours post-induction, cells were pelleted at 17,000g for five minutes and were lysed. 100 µl 
of 10 mg/mL lysozyme was added after the lysis buffer (50 mM NaH2PO4, 300 mM NaCl, pH 8.0) and 
cells were incubated on ice for 20 minutes. Lysed suspension was passed through a needle to ensure lysis is 
complete. Samples were centrifuged at 17,000g for five minutes and resupsended in 50 µl of 1X SDS 
buffer. A Bradford Assay was performed to determine protein concentration of the lysate. 15 µg, 20µg, and 
25 µg of protein were combined with 5 µl of 1X SDS loading buffer and run on a 4-15% SDS-PAGE gel at 
200V for 35 minutes. 
When sufficient ALKBH2 and ALKBH3 protein levels were confirmed, large scale growth and 
expression was performed following the same protocol as mentioned above. 2L of cells were grown and 
induced with 1M IPTG, washed with PBS, and pelleted equally into two 50 mL Falcon tubes. Cells were 
resuspended in lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 5 mM BME, 0.4 mM TSF, pH 8.0) and were 
additionally sonicated using a BioRuptor® PICO sonicator (Diagenode #B0106002) for 10 minutes. 0.2 
mg/mL DNAse was added to the lysed suspension prior to heating at 37°C for 15 minutes. Cells were then 
frozen at -45°C for five minutes and heated up at 37°C again for 15 minutes. Lysis suspension was 
centrifuged at 7,000g for 20 minutes and lysate was transferred to a new tube. 
 
FPLC-purification 
We sought to purify the ALKBH3 protein from the lysate using FPLC (GE Amersham 
Biosciences ÄKTA Explorer #18-1900-26) on a 1 mL His-Trap affinity column (GE Healthcare #17-5247-
01), allowing the binding of His-tagged proteins under low salt conditions, and elution of those proteins 
under high salt conditions. The binding buffer (20 mM Na2H2PO4x2H2O, 20 mM Na2H2PO4xH2O, 500 mM 
NaCl, 20 mM Imidazole, pH 7.4) was 0.2 µm filter-sterilized. Seven milliliters of protein lysate were 
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loaded onto the column and washed with the low-salt binding buffer at a flow rate of 0.5 mL/min and the 
flowthrough was collected. The column was then eluted with a high-salt buffer ((20 mM Na2H2PO4x2H2O, 
20 mM Na2H2PO4xH2O, 500 mM NaCl, 500 mM Imidazole, pH 7.4) over 40 minutes at a flow rate of 0.5 
mL/min and fractions were collected. Flowthrough and elution fractions were run on a 4-15% SDS-PAGE 
gel to observe purity of the protein. 
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RESULTS 	  
 
CRISPR-Cas9 ALKBH2 and ALKBH3 Genomic Targeting Sequences 
RNA-guided targeting sequences specific to the ALKBH2 and ALKBH3 genomes were 
designed using the CRISPR Design Tool. The vectors were chosen such that the targeting frame 
of all variants would be disrupted, thus eliminating protein activity. The targeting sequences that 
were designed and used are found in Table 2. 
 
PCR analysis of isolated genomic DNA from ALKBH2 and ALKBH3 targeted clones 
PCR analysis of the genomic DNA isolated from the ALKBH2 and ALKBH3 clones 
confirmed successful amplification of respective DNA fragments. Fragment analysis of the PCR 
products from the HTERTG subclones that amplified the CRISPR-Cas9 cutting site showed no 
allele knockout in ALKBH2 clones with respect to wild type HTERTG (Figure 13). However, 
fragment analysis results for one clone from cells transfected with the ALKBH3 CRISPR-Cas9 
construct showed what was suspected to be a single base-pair insertion as the peak for the wild 
type HTERTG sample showed a mass of 616.32 nucleotide fragment. ALKBH3 Clone 12 showed 
a peak at 616.30 nt, representing the wild type allele, as well as a peak of equal intensity at 
617.55 (Figure 14). 
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Table 3. Analysis of ALKBH2 clones 
ALKBH2 Clone number Genotype (Fragment Analysis) 
1 WT (wild type) 
2 WT 
4 WT 
6 WT 
8 WT 
12 WT 
13 WT 
14 WT 
15 WT 
16 WT 
17 WT 
18 WT 
20 WT 
23 WT 
24 WT 
 
Table 4. Analysis of ALKBH3 clones 
 
ALKBH3 Clone number Genotype (Fragment Analysis) 
1 WT (wild type) 
2 WT 
3 WT 
5 WT 
12 WT/insertion 
13 WT 
15 WT 
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Figure 13. Fragment analysis results of ALKBH2-targeted clones. A) Fragment analysis results of 
negative control wild type hTERTG. Results show two peaks of size 324.7nt (expected size of PCR 
fragment) and 311.22nt (unknown).  B) Fragment analysis results of hTERTG ALKBH2 Clone 2. Results 
show two peaks of equal intensity to those seen in wild type results.  	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Figure 14. Fragment analysis results of ALKBH3-targeted clones. A) Fragment analysis results of 
negative control wild type hTERTG. Results show one peak of size 616.32nt (expected size of PCR 
fragment)). B) Fragment analysis results of hTERTG ALKBH3 Clone 12. Results show two peaks of equal 
intensity, one of which correlates to the wild type allele and another peak one nucleotide larger, indicating 
there may be a single base pair insertion into the sequence of Clone 12. 	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Sequence confirmation of base pair insertion in ALKBH3 Clone 12 
 
To confirm the fragment analysis results indicating a single base pair insertion in the 
sequence of ALKBH3 Clone 12, the isolated genomic DNA from Clone 12 was ligated into a 
pENQUIS-TA vector and transformed into Qiagen EZ Competent Cells. Ampicillin-resistant 
colonies were selected and plasmids from four colonies were isolated and sent to the Integrated 
Genomics Core Facility at City of Hope to be sequenced. In order to eliminate ALKBH2 or 
ALKBH3 protein activity, the open reading frames must be disrupted and that can occur via an 
insertion or deletion of bases so long as they are not in multiples of three. The targeting vectors 
that were used to disrupt the respective ALKBH2 and ALKBH3 DNA sequences were acting 
within the exons that would disrupt the open reading frame and prevent translation of the protein 
(Figure 15-16). Sequencing results showed that with respect to the known sequence of ALKBH3, 
the transfected ALKBH3 Clone 12 had a single nucleotide insertion (thymine) (Figure 17).   
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Figure 15. CRISPR-Cas9 targeting sites within ALKBH2 genome. ALKBH2 
genome shows the Cas9 targeting sites falls within the translated mRNA region of 
every variant, indicating a disruption of the open reading frame and elimination of 
protein activity. Two targeting sites exist within Exon 2 of the genome. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure 14. CRISPR-Cas9 targeting sites within ALKBH2 genome. ALKBH2 
genome shows the Cas9 targeting sites falls within the translated mRNA region of 
every variant, indicating a disruption of the open reading frame and elimination of 
protein activity. Two targeting sites exist within Exon 2 of the genome. 
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Figure 16. CRISPR-Cas9 targeting sites within ALKBH3 genome. ALKBH3 
genome shows the Cas9 targeting sites falls within the translated mRNA region of 
every variant, indicating a disruption of the open reading frame and elimination of 
protein activity. Two targeting sites exist, one within Exon 5 and the other within 
Exon7. The sequence highlighted is the targeting site found within Exon 5 and the 
sequence that was targeted in this study. 	  	  	  	  	  	  	  	  	  	  	  	  
 
 
Figure 15. CRISPR-Cas9 targeting sites within ALKBH3 genome. ALKBH3 
genome shows the Cas9 targeting sites falls within the translated mRNA region of 
every variant, indicating a disruption of the open reading frame and elimination of 
protein activity. Two targeting sites exist, one within Exon 5 and the other within 
Exon7. The sequence highlighted is the targeting site found within Exon 5 and the 
sequence that was targeted in this study. 
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Purification of ALKBH3 
In order to compare activity levels of the ALKBH2 and ALKBH3 proteins within HTERTG cells 
that are deficient or aberrant in the respective genes, purified ALKBH2 and ALKBH3 proteins 
were purified to serve as controls.  
In order to compare ALKBH3 protein expression in homozygous ALKHB3 double-
knockout HTERTG cells, the purified protein was prepared as a control for oxidative 
demethylation. The ALKBH2 and ALKBH3 plasmids were transformed into 
Rosetta™(DE3)pLysS competent cells, expanded into a 50mL culture, induced with IPTG, lysed, 
and expressed on an SDS-PAGE gel for visualization of protein levels (Figure 18). 5mL of the 
50mL culture was expanded into 500mL of LB and induced with IPTG. Cells were pelleted, 
lysed, and lysate was subjected to fast protein liquid chromatography (FPLC) using a His-Tag 
1mL column. Flow through and protein elution fractions were collected and run on an SDS-
PAGE gel to indicate purity of the ALKBH3 protein fractions (Figure 19).  
	  	  	  	  	  
 
Figure 17. Comparison of wild type and Clone 12 ALKBH3 DNA sequences. Wild type 
ALKBH3 DNA sequence is denoted by ALKBH3 Control. E.coli colonies represent individual 
colonies with the amplified PCR fragment inserted from the ALKBH3 Clone 12 that had their 
plasmids isolated and sequenced. Results show Colony 6 includes a thymine base insertion, (outlined 
in red box), confirming the fragment analysis results.  	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Figure 18. Protein activity expression of Rosetta cells after IPTG induction. 4-15% SDS-
PAGE gel showing protein activity levels of Rosetta cells expressing ALKBH2 and ALKBH3 
plasmids induced by IPTG after OD600 of 0.5 was reached. ALKBH3 has a molecular weight 
of 33,375 Da. ALKBH2 is slightly smaller at a molecular weight of 31,400 Da. BioRad 
Precision Plus All Blue was used as a molecular weight marker (BioRad #161-0373). 
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Figure 19. Expression of FPLC-purified fractions of ALKBH3 protein lysate. ALKBH3 
protein lysate was run on FPLC under a 150-500mM imidazole gradient over 40.00 minutes. 
4-15% Mini-PROTEAN® TGXTM SDS-PAGE gel showing FPLC-purified ALKBH3 protein 
flowthrough and imidazole elution fractions. Results show nearly pure protein product.  
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DISCUSSION 
The goal of this study was to investigate the biological roles of the direct reversal DNA 
repair proteins, ALKBH2 and ALKBH3 in human cells. Primary mouse embryonic fibroblasts 
deficient in Alkbh2 or Alkbh3 have increased susceptibility to SN2 alkylating agents, suggesting 
that these proteins play a significant role in preventing and repairing DNA damage due to 
methylation as well as decreasing the frequency of mutagenic alkyl adducts (Nay et al., 2012). In 
this study, we targeted the ALKBH2 and ALKBH3 genes in telomerase immortalized human skin 
fibroblasts with a CRISPR/Cas9-designed construct. That ultimate goal was not attained, but we 
were able to demonstrate that the HTERTG fibroblasts can be expanded and serve as a model in 
which to construct targeted human cell lines that have near normal karyotypes. Of the several 
clones that were isolated after transfection with the ALKBH targeting sequence, one clone 
(ALKBH3 Clone 12) was identified that had undergone heterozygous targeting on one allele. The 
failure to obtain more ALKBH2 or ALKBH3-deficient clones will be discussed below. 
 
Generation of in vitro mammalian ALKBH2 and ALKBH3-deficient models  
For this study, we used telomerase immortalized human skin fibroblasts from the 
HTERTG cell line. Transfection efficiency of these cells with the CRISPR/Cas9-designed 
targeting vector in combination with GFP was visualized using microscopy. Transfection 
efficiency was consistently >90% when observed qualitatively. However, our results show that 
very few clones that were isolated after transfection were actually targeted for the ALKBH2 or 
ALKBH3 alleles, as was confirmed by fragment analysis (Figures 12-13). These results suggest a 
couple of things. There may have been poor transfection of the cells. Alternatively, during the 
time the cells were maintained post-transfection before clones were isolated, the double stranded 
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break in the DNA induced by the CRISPR/Cas9 construct may not have occurred successfully, or 
the cells’ intrinsic properties allowed repair of the break before the DNA was isolated from the 
clones. This would result in clones that were initially targeted, but were repaired before analysis. 
An experimental observation that could have contributed to the isolation of minimal clones is that 
the cells used in this study were transfected at late-passage. They were transfected after 27 
passages and some isolated clones did not divide properly, which could have been the result of 
their late stage. By the end of the isolation of clones, the cells had been pushed to the limit of 
their utility, as was observed based on their abnormal divisions and morphology. For future work, 
these cells should be transfected and isolated at a much earlier passage.  
Another factor in the limited number of clones isolated is the cloning method used. In this 
study, there was no selection for clones that were successfully transfected. Literature has shown 
other methods that prove to be quite successful in isolation of targeted clones. The 2009 study 
done by Xia Chen on the isolation of telomerase immortalized fibroblasts showed that transfected 
clones were further selected with G418 disulfate salt, which is an aminoglycoside antibiotic 
(Chen and Thibeault, 2009). Using some form of selection for the isolation of clones in our study 
may have increased the potential for isolating targeted clones. 
HTERT (human telomerase reverse transcriptase) cells are telomerase-immortalized 
human skin fibroblasts, preventing telomere-controlled senescence(Ouellette et al., 2000a; 
Ouellette et al., 2000b). Following their immortalization with HTERT, primary human cells 
remain near normal—diploid, differentiated, contact-inhibited, and non-tumorigenic (Lee et al., 
2004). These cells allow the extended use of these cells without developing cancer-associated 
properties. With respect to this study, the use of these near-normal HTERT cells may have been a 
factor in the limited number of ALKBH2 or ALKBH3-targeted clones isolated. It could be 
suggested that the double-stranded breaks induced in the DNA of these cells by the CRISPR/Cas9 
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targeting vector was repaired via the intrinsic properties of the cells themselves. For future 
directions, a different cell type could be utilized that is known to not repair DNA damage as 
quickly. 
 
Analysis of isolated clones 
From the ALKBH2-targeted cells, fifteen clones were isolated and analyzed (Table 3). 
From the ALKBH3-targeted cells, seven clones were isolated and analyzed (Table 4). The 
ALKBH2 clones, when analyzed using PCR and fragment analysis, did not show successful 
targeting of either allele. However, for the ALKBH3 clones, Clone 12 was targeted on one allele.  
 
Fragment Analysis  
Fragment analysis is a general term used to describe genetic marker analysis experiments 
which rely on detection of changes in the length of a specific DNA sequence to indicate the 
presence or absence of a genetic marker. Marker analysis is a general genetic technique in which 
the sequence of the gene is not directly analyzed, but the presence of a particular allele or mutant 
version of the allele of the gene is inferred from the presence or absence of a linked DNA 
sequence which can serve as a marker for the allele. Our fragment analysis results for the 
ALKBH2-targeted DNA show no difference in fragment size between the transfected cells and 
their wild type counterparts (Figure 12). The ALKBH3-targeted DNA for Clone 12, however, did 
show a peak of equal intensity as the wild type peak with a fragment size that was one base pair 
greater than the wild type (Figure 13). This study utilized a 500nt LIZ marker as the standard 
against which samples are tested. The expected fragment size of the wild type PCR product was 
615bp with the M13(-21) tag included. However, the fragment analysis results show a fragment 
size of 616.32nt for the wild type sample. Furthermore, the additional peak seen in the results for 
ALKBH3 Clone 12 had a size of 617.55nt. This suggested that, perhaps, because the expected 
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fragment size was out of the range of the 500nt LIZ marker used as a standard, the resulting 
fragments of the ALKBH3 samples were not completely accurate. It was not possible to conclude 
that the DNA sequence of Clone 12 had a one or two base insertion. For future direction, a 
marker with a larger range of fragment sizes could be use to more accurately determine what the 
true fragment size of the PCR product is.	  	  
Protein Purification	  	  
Wild type ALKBH2 and ALKBH3 proteins were purified to serve as a control for 
oxidative demethylation. Cells expressing the respective plasmid were induced with IPTG and 
grown for an hour and a half at 37°C, lysed, and lysates were expressed on an SDS-PAGE gel 
(Figure 16). Lysates were then run on a 1-mL His-Trap column under FPLC on a 150-500mM 
imidazole gradient and fractions were collected and expressed on an SDS-PAGE gel (Figure 17). 
The initial purification of the ALKBH3 protein via FPLC was not photographically pure (Figure 
17). The proteins are both basic with isolelectric points above 9, meaning that they are positively 
charged. Therefore, it is possible to use a Mono S cation exchange column to purify further the 
His-tag-ALKBH2 and His-tag-ALKBH3 proteins. 	  	  
Future Direction	  
To achieve the original goals, different techniques for use of the cells with the CRISPR-
Cas9 construct could potentially allow for higher targeting potential. One suggested direction 
would be to alter the method of targeting the ALKBH2 and ALKBH3 genes. Lentiviral vector 
targeting has been used successfully to target various genes within a several different types of 
cells. One study has shown that lentiviral vector targeting has been used to suppress myostatin 
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gene expression in goat fibroblasts (Patel et al., 2014). This study could utilize this method of 
targeting the ALKBH2 and ALKBH3 alleles for improved results. 	  
Another improvement that can be applied to this study would be the use of a different cell 
type. We discussed the potential problems that may have occurred with the HTERTG fibroblasts. 
The HAP1 cell line is a fibroblast-like cell that was derived from the KBM7 cell line 
(Burckstummer et al., 2013). It is a cancer-cell line that is unique in that it is near-haploid, 
meaning it contains only one copy for most of its chromosomes (Essletzbichler et al., 2014). This 
could be beneficial to our study, because targeting ALKBH2 or ALKBH3 would only require one 
allele to be hit, possibly making the targeting more successful. Another cell type that could be 
utilized is the HT1080 cell line. The HT1080 cells are a fibrosarcoma cell that is diploid (Rasheed 
et al., 1974). The benefit to using these cells is their rapid dividing potential. This would allow for 
the isolation of clones in a more timely manner and prevent the over usage of the cells. 	  
Another improvement would be in the selection of targeted clones. Transfection of cells 
is quite stress-inducing, and the likelihood of all cells surviving is not high. Furthermore, we did 
not utilize any type of selection when isolating clones. Therefore, it was not fully determined that 
the clones isolated had been transfected properly and thus, targeted. This study utilized co-
transfection with GFP to observe transfection efficiency. However, using a method that will 
select for the individual cells that express the GFP plasmid, and hopefully also the CRISPR 
targeting vector, and expanding those will increase the likelihood of the ALKBH2 or ALKBH3 
gene also being targeted by the CRISPR-Cas9 construct. Studies have been done using what is 
known as a Fluorescence Activated Cell Sorter (FACS) to select individual cells expressing the 
GFP plasmid (Meng et al., 2000). This may allow for the successful expansion of an ALKBH2 or 
ALKBH3 double-knockout cell line to be able to characterize the effects of these deficiencies on 
cell survival and mutation accumulation. 
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